Johnson and Johnson 2014 Annual Report Download - page 8

Download and view the complete annual report

Please find page 8 of the 2014 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 84

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84

(golimumab) and REMICADE® (infliximab), biologics
approved for the treatment of a number of immune-
mediated inflammatory diseases.
When it comes to innovation and ensuring we have
continuous access to new ideas and products at their
earliest stages, we expect the best science to prevail
regardless of whether that comes from sources inside
or outside of Johnson & Johnson. In 2014, we made
two significant acquisitions to add to our innovation
portfolio: Alios BioPharma, Inc., a privately-held clinical
stage biopharmaceutical company focused on developing
therapies for viral diseases; and Covagen AG, a privately-
held biopharmaceutical company specializing in the
development of multispecific protein therapeutics through
the FynomAb® technology platform.
MEDICAL DEVICES
Worldwide Medical Devices sales of $27.5 billion for the
full-year 2014 represented an operational decrease of
1.6 percent. Excluding the net impact of acquisitions and
divestitures, on an operational basis, worldwide sales
increased 1.6 percent.†
The Medical Devices business holds a strong leadership
position in the industry, including 10 platforms with more
than $1 billion in sales. We’ve launched over 50 major
new products since 2012, and have more than 30 major
new filings planned by the end of 2016.
PHARMACEUTICALS
Worldwide Pharmaceutical sales of $32.3 billion for
the full-year 2014 represented operational growth of
16.5 percent. With 14 new medicines launched since
2009, our Pharmaceutical segment is the fastest
growing of the top 10 pharmaceutical businesses in
the U.S., Europe and Japan**, and our medicines are
making a dramatic impact.
The strong sales results were driven by new products
and the strength of our core products. New products
include OLYSIO®/SOVRIAD® (simeprevir), for
combination treatment of chronic hepatitis C in adult
patients; XARELTO® (rivaroxaban), an oral anticoagulant;
ZYTIGA® (abiraterone acetate), an oral, once-daily
medication for use in combination with prednisone for
the treatment of metastatic, castration-resistant prostate
cancer; INVOKANA® (canagliflozin), for the treatment of
adults with type 2 diabetes; and IMBRUVICA® (ibrutinib),
an oral, once-daily therapy approved for use in treating
certain B-cell malignancies, or blood cancers.
Additional contributors to operational sales growth were
STELARA® (ustekinumab), a biologic approved for the
treatment of moderate to severe plaque psoriasis and
psoriatic arthritis; INVEGA® SUSTENNA®/XEPLION®
(paliperidone palmitate), a once-monthly, long-acting,
injectable atypical antipsychotic for the treatment of
schizophrenia in adults; SIMPONI®/SIMPONI ARIA®
2014 BUSINESS HIGHLIGHTS
2014 was a strong year for Johnson & Johnson, as we delivered solid financial results
while continuing to make investments to accelerate growth for the long term. We have
built significant momentum in our Pharmaceutical business, are realizing the benefits
of innovation, scale and breadth in our Medical Devices business and are continuing our
market leadership with iconic brands in our Consumer business. We’ve achieved our
near-term priorities, exceeding our financial targets with full-year operational* sales growth
of 6.1 percent. Excluding the net impact of acquisitions and divestitures, on an operational
basis, worldwide sales increased 8.0 percent.†
VI • 2014 BUSINESS HIGHLIGHTS